Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Ylä-Herttuala, S
Right arrow Articles by Dzau, V.J
Right arrow Search for Related Content
PubMed
Right arrow Articles by Ylä-Herttuala, S
Right arrow Articles by Dzau, V.J
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

The European Society of Cardiology

Introduction

S Ylä-Herttualaa,*,1 and V.J Dzaub,2

a Al Virtanen Institute, University of Kuopio, Kuopio, Finland
b Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA

* Correspondence to: Ylä Herttuala, Department of Molecular Medicine and Gene Therapy Unit, P.O. Box 1627, Kuopio University Hospital, Puijonlaaksontie 2 (P.O. Box 1777), Kuopio 70210, Finland. Tel.: +358-17-162075; fax: +358-17-163030/163751
seppo.ylaherttuala@uku.fi

The first 10% of the full text of this article appears below.

The development of angiogenic therapy to treat coronary artery disease (CAD) results from the convergence of two major trends over the past few decades: the increasing incidence of cardiovascular disease with its associated patient morbidity, and the availability of genetic techniques for clinical application.

Cardiovascular . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?